Brokerages forecast that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will report earnings per share of ($0.72) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Dova Pharmaceuticals’ earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.77). Dova Pharmaceuticals posted earnings per share of ($0.36) during the same quarter last year, which suggests a negative year over year growth rate of 100%. The business is scheduled to issue its next quarterly earnings results on Thursday, February 21st.

According to Zacks, analysts expect that Dova Pharmaceuticals will report full year earnings of ($2.63) per share for the current year, with EPS estimates ranging from ($2.69) to ($2.57). For the next fiscal year, analysts forecast that the company will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.78) to ($1.04). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Dova Pharmaceuticals.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Thursday, November 8th. The company reported ($0.69) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.12. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $2.66 million.

A number of equities analysts recently issued reports on the company. Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Wednesday, October 10th. BidaskClub raised Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 13th. Leerink Swann lowered their price target on Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a report on Tuesday, September 4th. Finally, Raymond James assumed coverage on Dova Pharmaceuticals in a report on Wednesday, August 29th. They set an “outperform” rating and a $44.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Dova Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $33.20.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DOVA. Metropolitan Life Insurance Co. NY purchased a new position in shares of Dova Pharmaceuticals during the second quarter worth about $128,000. JPMorgan Chase & Co. grew its holdings in shares of Dova Pharmaceuticals by 148.6% during the first quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock worth $145,000 after buying an additional 3,195 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Dova Pharmaceuticals during the third quarter worth about $145,000. Tower Research Capital LLC TRC purchased a new position in shares of Dova Pharmaceuticals during the third quarter worth about $158,000. Finally, Bank of America Corp DE grew its holdings in shares of Dova Pharmaceuticals by 81.3% during the second quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock worth $159,000 after buying an additional 2,379 shares during the last quarter. 36.53% of the stock is currently owned by hedge funds and other institutional investors.

Shares of DOVA traded up $1.27 during midday trading on Thursday, reaching $15.39. 199,700 shares of the stock were exchanged, compared to its average volume of 211,617. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.40 and a current ratio of 7.50. Dova Pharmaceuticals has a twelve month low of $14.09 and a twelve month high of $37.00. The stock has a market capitalization of $466.78 million, a P/E ratio of -10.99 and a beta of 0.87.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Further Reading: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.